Panduan definitif tentang penyuntingan gen.
★
Menu
Beranda Pelajari Berita
Jelajahi Teknologi Penyakit Perawatan Uji Klinis Perusahaan Ilmuwan Gen-gen Penelitian Institusi
Di luar dunia medis Pertanian Etika Investasi Peta dunia
Pelajari & Alat Mulai di sini Glosarium A–Z Bandingkan teknologi Linimasa Daftar & Peringkat Agen AI ★ Tersimpan API
Tentang Tentang kami Metodologi Sumber Data Kebijakan Editorial Kontak Penafian

Tampilan Terpandu
Baru mengenal genetika? Kami menjelaskan setiap istilah saat kamu menjelajah, dalam bahasa yang mudah dipahami. Halaman yang sama, dengan bantuan yang sudah tersedia.

Pandangan Ahli
Kamu sudah mengenal biologinya. Cukup kontennya, ringkas dan padat, tanpa penjelasan tambahan. Ini adalah tampilan default.

Bahasa antarmuka
Mode terang

Treatment · Cancer

CB-010

An allogeneic CAR-T candidate built with hybrid RNA-DNA guides rather than conventional guide RNAs, intended to cut off-target editing.

Phase I cell therapyallogeneicCas12a
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

Penjelasan sederhana

Caribou builds its edited cells using a modified kind of guide, part RNA and part DNA, which the company says makes the editing machinery fussier about where it cuts. CB-010 is an off-the-shelf CAR-T made this way, with an extra edit that removes a brake on the engineered cells so they keep working longer.

Pelajari lebih dalam

CB-010 is an allogeneic anti-CD19 CAR-T candidate from Caribou Biosciences produced using chRDNA (hybrid CRISPR RNA-DNA) guides with Cas12a, incorporating TRAC insertion of the CAR and PDCD1 knockout to improve persistence. In development for B-cell non-Hodgkin lymphoma and autoimmune indications.

Sources

Written by CRISPR Decoded editorial team Last updated Oct 27, 2026

Connected in CRISPR Decoded

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Technologies

CRISPR-Cas12

Diseases

Leukemia and Lymphoma

Clinical Trials

A Study of CB-010 in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Genes

PDCD1TRAC

Companies

Caribou Biosciences
Hanya informasi edukatif Halaman ini adalah referensi, bukan nasihat medis. Status riset dan regulasi dapat berubah; periksa tanggal pembaruan terakhir di atas dan konfirmasi hal-hal penting dengan sumber primer yang tercantum.